Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Macular Edema - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Macular Edema - Pipeline Review, H1 2015', provides an overview of the Macular Edema's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Macular Edema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Macular Edema Overview 7 Therapeutics Development 8 Pipeline Products for Macular Edema - Overview 8 Pipeline Products for Macular Edema - Comparative Analysis 9 Macular Edema - Therapeutics under Development by Companies 10 Macular Edema - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Macular Edema - Products under Development by Companies 14 Macular Edema - Companies Involved in Therapeutics Development 15 Allergan, Inc. 15 Clearside BioMedical, Inc. 16 F. Hoffmann-La Roche Ltd. 17 Pfizer Inc. 18 Promedior, Inc. 19 Regeneron Pharmaceuticals, Inc. 20 Taiwan Liposome Company, Ltd. 21 Macular Edema - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Combination Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 (triamcinolone acetonide + aflibercept) - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 aflibercept (recombinant) - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 beclomethasone dipropionate - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 celecoxib - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 dexamethasone acetate SR - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 PRM-167 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ranibizumab - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ranibizumab SR - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 triamcinolone acetonide - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Macular Edema - Recent Pipeline Updates 47 Macular Edema - Dormant Projects 63 Macular Edema - Discontinued Products 64 Macular Edema - Product Development Milestones 65 Featured News & Press Releases 65 Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion 65 Jan 23, 2015: EYLEA(aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union 65 Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC's Ophthalmology Drug Phase I/II trial 66 Oct 06, 2014: EYLEA (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) 66 Sep 04, 2014: Regeneron Announces Submission of Application for EYLEA (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion 67 Feb 25, 2014: NICE gives green light to treatment for macular oedema in final guidance 67 Feb 24, 2014: Regeneron Announces FDA Acceptance of EYLEA (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 68 Dec 27, 2013: NICE gives green light to treatment for macular oedema in final draft guidance 69 Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug 69 Nov 22, 2013: EYLEA Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72
List of Tables
Number of Products under Development for Macular Edema, H1 2015 8 Number of Products under Development for Macular Edema - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Macular Edema - Pipeline by Allergan, Inc., H1 2015 15 Macular Edema - Pipeline by Clearside BioMedical, Inc., H1 2015 16 Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 17 Macular Edema - Pipeline by Pfizer Inc., H1 2015 18 Macular Edema - Pipeline by Promedior, Inc., H1 2015 19 Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 20 Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Assessment by Combination Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 31 Macular Edema Therapeutics - Recent Pipeline Updates, H1 2015 47 Macular Edema - Dormant Projects, H1 2015 63 Macular Edema - Discontinued Products, H1 2015 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.